ASPIRIN SODIUM

US Approved OTC

First marketed in 1899

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H7O4.Na
Molecular Weight	202.1396
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)Oc1ccccc1C(=O)[O-].[Na+]

InChI

InChIKey=JZLOKWGVGHYBKD-UHFFFAOYSA-M

InChI=1S/C9H8O4.Na/c1-6(10)13-8-5-3-2-4-7(8)9(11)12;/h2-5H,1H3,(H,11,12);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	C9H7O4
Molecular Weight	179.1498
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011483s029lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/11723249

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostaglandin G/H synthase 1 29 Target ID: P23219\|\|\|Q5T7T7 Gene ID: 5742.0 Gene Symbol: PTGS1 Target Organism: Homo sapiens (Human) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200671s000lbl.pdf	Inhibitor 7728		1.2 µM [IC50]
Prostaglandin G/H synthase 2 46 Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011483s029lbl.pdf	Inhibitor 7728		5.2 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Pain 580 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011483s029lbl.pdf	Primary	Approved 8043	SYNALGOS-DC Approved Use SYNALGOS-DC is a combination of dihydrocodeine, an opioid agonist, aspirin, a nonsteroidal anti-inflammatory drug, and caffeine, a methylxanthine, and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Launch Date -3.62620813E11
Headache 46 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00c6776-e9ef-411b-9396-915c3787559a	Primary	Approved 8043	FIORINAL Approved Use FIORINAL is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Fiorinal in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. Launch Date 2.00016003E11
Myocardial infarction 92 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200671s000lbl.pdf	Preventing	Approved 8043	DURLAZA Approved Use DURLAZA is a nonsteroidal anti-inflammatory drug indicated to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina and to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack. Launch Date 1.44132486E12
Stroke 138 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20884_AGGRENOX_prntlbl.pdf	Preventing	Approved 8043	AGGRENOX Approved Use AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Launch Date 9.4322878E11

C_max

Value	Dose	Co-administered	Analyte	Population
54.25 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.84 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
10.31 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5.12 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.322 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.422 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
68% REVIEW https://www.ncbi.nlm.nih.gov/pubmed/30115648			ASPIRIN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1601 inducer 707	substrate 936	substrate 1118 inducer 97

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT3 588	CYP1A2 972 CYP2A6 485 CYP2B6 616 CYP2C8 634 CYP2C19 910 CYP2E1 606 esterase 63 UGT1A1 393 UGT1A3 397 UGT1A6 289 UGT1A7 221 UGT1A8 266 UGT1A9 357 UGT1A10 273 UGT2B4 233 UGT2B7 362 P-gp 1400	CYP2C19 269 CYP1A2 637 CYP2E1 117 ABCA1 18 P-gp 248

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1532	inducer 1440 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1067/mcp.2003.14 Page: -	no
CYP2D6 1738	inducer 1440 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1067/mcp.2003.14 Page: -	no
CYP2E1 871	inducer 1440 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1067/mcp.2003.14 Page: -	no
ABCA1 18	inducer 1440 Sources: https://www.karger.com/Article/Abstract/321727 Page: -	yes
CYP2C19 1392	inducer 1440 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes
CYP3A4 1772	inducer 1440 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes
OAT3 590	inhibitor 3045 Sources: https://dmd.aspetjournals.org/content/42/6/996.short Page: -	yes
P-gp 1514	inducer 1440 Sources: https://pubmed.ncbi.nlm.nih.gov/11205285/ Page: -	yes

Drug as victim

Target	Modality	Activity	Metabolite
CYP1A2 972	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP1A2 972	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no	salicylic acid 18
CYP2A6 485	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2B6 616	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2B6 616	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no	salicylic acid 18
CYP2C19 910	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2C8 634	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2C9 936	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2D6 1118	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP3A4 1601	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
P-gp 1400	substrate 3113 Sources: https://www.tandfonline.com/doi/full/10.1080/00498254.2020.1757785 Page: -	no
UGT1A8 266	substrate 3113 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	no	salicylic acid 18
UGT2B4 233	substrate 3113 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	no	salicylic acid 18
UGT2B7 362	substrate 3113 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 1242 uM]	salicylic acid 18
UGT1A3 397	substrate 3113 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 2337 uM]	salicylic acid 18
UGT1A7 221	substrate 3113 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 278.6 uM]	salicylic acid 18
UGT1A6 289	substrate 3113 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 40.7 uM]	salicylic acid 18
UGT1A1 393	substrate 3113 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 683.1 uM]	salicylic acid 18
UGT1A10 273	substrate 3113 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 698.2 uM]	salicylic acid 18
UGT1A9 357	substrate 3113 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 94.2 uM]	salicylic acid 18
CYP2A6 485	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2C19 910	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2C8 634	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2C9 936	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2D6 1118	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2E1 606	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP3A4 1601	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
esterase 63	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B1-00059	http://www.3bsc.com/index/pro_info.php?id=20271
AA Blocks	AA00I8UA	http://www.aablocks.com/goods/Goods/detail?id=AA00I8UA
AK Scientific, Inc. (AKSCI)	H740	http://www.aksci.com/item_detail.php?cat=H740
Aaron Chemicals	AR00I9M2	http://www.aaronchem.com/50-78-2
AbMole Bioscience	M5426	http://www.abmole.com/products/aspirin.html
Acadechem	ACDS-070196	http://www.acadechemical.com/product/144895
Achemica	ACMC-209kpz	http://www.achemica.com/prodinfo/?id=128318
Achemo Scientific Limited	AC-24217	http://www.achemo.com/search/?Keyword=50-78-2
Achemtek	0104-001327	http://www.achemtek.com/50-78-2
Acros Organics	AC158180500	https://www.fishersci.com/shop/products/acetylsalicylic-acid-99-acros-organics-1/AC158180500
Acros Organics	AC158185000	https://www.fishersci.com/shop/products/acetylsalicylic-acid-99-acros-organics-1/AC158185000
Acros Organics	AC158180025	https://www.fishersci.com/shop/products/acetylsalicylic-acid-99-acros-organics/AC158180025
Alfa Aesar	A12488	https://www.alfa.com/en/catalog/A12488/
Ambinter	Amb17757514	http://www.ambinter.com/reference/17757514
Angene	AGN-PC-0WACEM	http://www.angenechemical.com/productshow/AGN-PC-0WACEM.html
Anward	ANW-31125	http://www.anward.com/pro_result/20981
ApexBio Technology	A4013	http://www.apexbt.com/aspirin-acetylsalicylic-acid.html
Aurora Fine Chemicals LLC	A00.156.463	http://online.aurorafinechemicals.com/info?ID=A00.156.463
Aurora Fine Chemicals LLC	K00.801.915	http://online.aurorafinechemicals.com/info?ID=K00.801.915
Avantor Inc	TCA2262-25G	https://us.vwr.com/store/product/9983116/o-acetylsalicylic-acid-98-0-by-gc-titration-analysis
BOC Sciences	1173022-25-7	https://isotope.bocsci.com/product/acetylsalicylic-acid-13c-cas-1173022-25-7-343874.html
BOC Sciences	97781-16-3	https://www.bocsci.com/2-acetoxybenzoic-3-4-5-6-d4-acid-cas-97781-16-3-item-212339.html
BOC Sciences	921943-73-9	https://www.bocsci.com/acetylsalicylic-acid-d3-cas-921943-73-9-item-466862.html
BioChemPartner	BCP21790	http://www.biochempartner.com/50-78-2-BCP21790
BioCrick	BCC2097	http://www.biocrick.com/Aspirin-Acetylsalicylic-acid-BCC2097.html
Boerchem	BC221833	http://www.boerchem.com/?product_37473.html
Capot Chemical	20190	http://www.capotchem.com/en/20190.htm
Capot Chemical	PubChem20190	http://www.capotchem.com/en/20190.htm
Chem Scene	CS-2001	http://www.chemscene.com/50-78-2.html
ChemMol	49417180	http://www.chemmol.com/chemmol/49417180.html
ChemMol	99097732	http://www.chemmol.com/chemmol/99097732.html
Chemspace	CSSB00000210466	https://chem-space.com/CSSB00000210466
Clearsynth	CS-EG-00025	https://www.clearsynth.com/en/CSEG00025.html
Clearsynth	CS-ER-02340	https://www.clearsynth.com/en/CSER02340.html
Clearsynth	CS-T-01103	https://www.clearsynth.com/en/CST01103.html
Clearsynth	CS-T-47333	https://www.clearsynth.com/en/CST47333.html
DC Chemicals	DC8956	http://www.dcchemicals.com/product_show-Acetylsalicylic_acid.html
Debye Scientific	DS-017139	http://www.debyesci.com/cas_59096-14-9.html
Enamine	Z234893989	https://www.enaminestore.com/catalog/Z234893989
Finetech	FT-0655181	http://www.finetechnology-ind.com/prod/detail/pub/50-78-2.html
Finetech	FT-0661360	http://www.finetechnology-ind.com/prod/detail/pub/97781-16-3.html
Glentham Life Sciences	GL0865	http://www.glentham.com/products/product/GL0865/
Hairui	HR138909	http://www.hairuichem.com/en/product/50-78-2.html
LGC Standards	DRE-C10024000	https://www.lgcstandards.com/US/en/p/DRE-C10024000
LGC Standards	LGCAMP0133.00-11	https://www.lgcstandards.com/US/en/p/LGCAMP0133.00-11
LGC Standards	LGCFOR0133.00	https://www.lgcstandards.com/US/en/p/LGCFOR0133.00
LGC Standards	MM0133.00-0250	https://www.lgcstandards.com/US/en/p/MM0133.00-0250
Lab Network	LN00223310	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00223310
Matrix Scientific	134531	https://www.matrixscientific.com/134531.html
MedChem Express	HY-14654	https://www.medchemexpress.com/aspirin.html
MuseChem	A000653	https://www.musechem.com/product/A000653.html
Oakwood	101923	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=130521&ExtHyperLink=1
Parchem	30462	http://www.parchem.com/chemical-supplier-distributor/Aspirin-USP-2080B--020462.aspx
Parchem	12326	http://www.parchem.com/chemical-supplier-distributor/Aspirin-USP-26-002326.aspx
Parchem	30461	http://www.parchem.com/chemical-supplier-distributor/Aspirin-USP-3080--020461.aspx
Selleck Chemicals	S3017	http://www.selleckchem.com/products/aspirin-acetylsalicylic-acid.html
Sigma-Aldrich	239631_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/239631?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A0200000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/a0200000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A2093_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a2093?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A3160_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a3160?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1044006_USP	https://www.sigmaaldrich.com/catalog/product/usp/1044006?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S054539	http://www.sinfoobiotech.com/product/1057937
Smolecule	S519564	http://www.smolecule.com/products/s519564
Synthetic Heterocycles	AFA100669	http://www.synhet.com/products/AFA100669
TCI (Tokyo Chemical Industry)	A2262	http://www.tcichemicals.com/eshop/en/us/commodity/A2262/index.html
THE BioTek	bt-260267	https://www.thebiotek.com/product/inhibitors/bt-260267
Tocris	4092	https://www.tocris.com/products/aspirin_4092
Vitas-M Laboratory	BBL005469	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL005469&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
VladaChem	VL271248-100G	https://www.vladachem.com/product.php?products=50-78-2
Yuhao Chemical	RT12808	http://www.chemyuhao.com/50-78-2.html
abcr GmbH	AB113303	http://www.abcr.com/shop/en/AB113303
eNovation Chemicals	D408997	http://www.enovationchem.com/productDetails.asp?productID=D408997
iChemical	EBD47326	http://www.ichemical.com/products/50-78-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-3199019536	https://mcule.com/MCULE-3199019536/

PubMed

Title	Date	PubMed
Letter: Aspirin sensitivity: other drugs.	1975 Feb	1115460
Studies on the modification of renal lesions due to aspirin and oxyphenbutazone in the rat and the effects on the kidney of 2:4 dinitrophenol.	1976 Jul	1004943
Analgesic-induced renal papillary necrosis in the Gunn rat: the comparative nephrotoxicity of aspirin and phenacetin.	1976 Nov	1003266
Acetyl salicylic acid improves somatosensory evoked potentials in streptozotocin-diabetic rats.	1999 Dec	10624784
The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance.	1999 Dec	10609620
Seizures induced by NSAID.	1999 Jan	10195372
Aspirin and heparin in acute ischaemic stroke in older patients.	1999 Jul	10459730
Aspirin reduces experimental cerebral blood flow in vivo.	1999 Jul	10439430
Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis.	1999 Jul-Aug	10393408
Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders.	1999 Jun	10400483
Leptin in gastroprotection induced by cholecystokinin or by a meal. Role of vagal and sensory nerves and nitric oxide.	1999 Jun 18	10422768
Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.	1999 Mar	10193204
Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes.	1999 May	10328874
Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells.	1999 May 21	10395027
Regular use of analgesics is a risk factor for renal cell carcinoma.	1999 Oct	10507783
Iron deficiency anaemia and aspirin use in old age.	1999 Sep	10756616
Spontaneous compartment syndrome after thrombolytic therapy.	1999 Sep	10645301
NSAID-induced bronchospasm--a common and serious problem. A report from MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority.	1999 Sep	10561993
Prospective study of aspirin use and risk of stroke in women.	1999 Sep	10471421
Sulindac inhibits activation of the NF-kappaB pathway.	1999 Sep 17	10480951
Hypophysectomy and/or peroxisome proliferators strongly influence the levels of phase II xenobiotic metabolizing enzymes in rat testis.	1999 Sep 30	10528994
Sleep attacks (sleep episodes) with pergolide.	2000 Apr 15	10776749
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria.	2000 Aug	10982225
Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs.	2000 Feb 15	10706128
[Cholestatic hepatitis as a rare side effect of therapy with ticlopidine].	2000 Jul	10965556
Symptomatic secondary hemorrhagic transformation of ischemic Wallenberg's syndrome.	2000 Jun	10929277
Effect of vitamin E on aspirin-induced gastric mucosal injury in rats.	2000 Mar	10749339
Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.	2000 Mar	10681486
Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema.	2000 Sep	10984376
Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi's sarcoma inflammation?	2001	11158202
Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study.	2001 Feb	11161949
Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).	2001 Feb	11157179
Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people.	2001 Feb	11157173
Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia.	2001 Feb 2	11157665
Antithrombotic agents in coronary artery disease.	2001 Jan	11157652
Antithrombotic therapy in atrial fibrillation.	2001 Jan	11157649
Multiple endothelial injury in epicardial coronary artery induces downstream microvascular spasm as well as remodeling partly via thromboxane A2.	2001 Jan	11153757
Prehospital management of rapid atrial fibrillation: recommendations for treatment protocols.	2001 Jan	11146008
Anticoagulation and heart failure.	2001 Jan	11139802
Is optimal antithrombotic therapy after myocardial infarction well defined?	2001 Jan	11139799
Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.	2001 Jan	11138826
Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia.	2001 Jan	11137180
Effect of acetylsalicylic acid on endogenous I kappa B kinase activity in lung epithelial cells.	2001 Jan	11133489
Hypothesized treatment for migraines using low doses of tryptophan, niacin, calcium, caffeine, and acetylsalicylic acid.	2001 Jan	11133261
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.	2001 Jan	11119474
Low-grade exercise enhances platelet aggregability in patients with obstructive coronary disease independently of myocardial ischemia.	2001 Jan 1	11137827
Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis.	2001 Jan 15	11163537
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism.	2001 Jan 15	11145657
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.	2001 Jan 23	11157686
Drug Points: tachycardia associated with moxifloxacin.	2001 Jan 6	11141146

Patents

Sample Use Guides

In Vivo Use Guide

Severe pain: Initiate treatment with two capsules (1 capsule contains 16 mg dihydrocodeine bitartrate, 356.4 mg aspirin, and 30 mg caffeine) orally every 4 hours as needed for pain. Headache: One or 2 capsules (1 capsule contains 50 mg butalbital, 325 mg aspirin and 40 mg caffeine) every 4 hours. Total daily dose should not exceed 6 capsules. Prevention of stoke and heart attacks: the recommended dose is one capsule of aspirin (162.5 mg) once daily. Take the capsules with a full glass of water at the same time each day. Prevention of stroke (in combination with dipyridamole): the recommended dose is one capsule (200 mg dipyridamole and 25 mg aspirin) given orally twice daily.

Route of Administration: Enteral

In Vitro Use Guide

Human platelet-rich plasma was incubated with various aspirin concentrations (10, 20, 50, 100, 200, 300, 400, 500 uM) at 37C for up to 4.5 h. Platelet aggregation and thromboxane generation were measured. Inhibition of platelet aggregation and thromboxane formation by 10 uM aspirin was maximal by 90 min. There was progressive inhibition by 3 uM aspirin during incubation for 270 min. By the end of this time there was also significant inhibition by 1 uM aspirin.

Substance Class	Chemical Created by `admin` on `Sat Jun 26 09:57:20 UTC 2021` Edited by `admin` on `Sat Jun 26 09:57:20 UTC 2021`
Record UNII	E62HT5S2E9
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ASPIRIN SODIUM

Common Name

English

BENZOIC ACID, 2-(ACETYLOXY)-, SODIUM SALT (1:1)

Common Name

English

SALICYLIC ACID ACETATE, SODIUM SALT

Common Name

English

BENZOIC ACID, 2-(ACETYLOXY)-, SODIUM SALT

Common Name

English

ACETYLSALICYLATE SODIUM

Systematic Name

English

SALICYLIC ACID, ACETATE, SODIUM SALT

Common Name

English

ACETYLSALICYLATE SODIUM [VANDF]

Common Name

English

SODIUM O-ACETYLOXYBENZOATE

Common Name

English

SODIUM ACETYLSALICYLATE

Systematic Name

English

SODIUM O-ACETOXYBENZOATE

Common Name

English

ACETYLSALICYLATE SODIUM [WHO-DD]

Common Name

English

ACETYLSALICYLIC ACID, SODIUM SALT

Common Name

English

SODIUM ACETYLSALICYLIC ACID

Systematic Name

English

SODIUM ASPIRIN

Common Name

English

ASPIRIN SODIUM SALT

Common Name

English

Code System Code Type Description

CAS

493-53-8